All Stories

  1. Pediatrics imaging
  2. In vivo imaging of nanoparticle-labeled CAR T cells
  3. Disparate participation by gender of conference attendants in scientific discussions
  4. Artificial intelligence for bone cancer imaging
  5. Pediatric Spine
  6. Pediatric Molecular Imaging
  7. Pediatric Molecular Imaging
  8. Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial
  9. Iron oxide nanoparticles inhibit tumour growth by inducing pro-inflammatory macrophage polarization in tumour tissues
  10. Three-dimensional Radiologic Assessment of Chemotherapy Response in Ewing Sarcoma Can Be Used to Predict Clinical Outcome
  11. Macrophage phagocytosis alters the MRI signal of ferumoxytol-labeled mesenchymal stromal cells in cartilage defects
  12. White Paper on P4 Concepts for Pediatric Imaging
  13. Speeding up PET/MR for cancer staging of children and young adults
  14. Safety Report of Ferumoxytol for Magnetic Resonance Imaging in Children and Young Adults
  15. Imaging Tumor Necrosis with Ferumoxytol
  16. Progressing Toward a Cohesive Pediatric 18F-FDG PET/MR Protocol: Is Administration of Gadolinium Chelates Necessary?
  17. Reply to Dr. Vazquez et al. regarding current methods for reducing intussusception: external manual reduction with US assistance
  18. Clinical applications of iron oxide nanoparticles for magnetic resonance imaging of brain tumors
  19. Magnetic Resonance Imaging of Stem Cell Apoptosis in Arthritic Joints with a Caspase Activatable Contrast Agent
  20. Improved Approach for Chondrogenic Differentiation of Human Induced Pluripotent Stem Cells
  21. Value of 18F-FDG PET and PET/CT for Evaluation of Pediatric Malignancies
  22. Current methods for reducing intussusception: survey results
  23. ACR Committee on Pediatric Imaging Research
  24. Basic science research in pediatric radiology — how to empower the leading edge of our field
  25. 18F-FDG PET/CT scans for children and adolescents – Authors' reply
  26. Ionising radiation-free whole-body MRI versus 18F-fluorodeoxyglucose PET/CT scans for children and young adults with cancer: a prospective, non-randomised, single-centre study
  27. MR Imaging of Stem Cell Transplants in Arthritic Joints
  28. Pediatric Molecular Imaging
  29. Pearls and Pitfalls in Pediatric Imaging
  30. Ferumoxytol: a new, clinically applicable label for stem-cell tracking in arthritic joints with MRI
  31. Iron Administration before Stem Cell Harvest Enables MR Imaging Tracking after Transplantation
  32. Development of Novel Tumor-Targeted Theranostic Nanoparticles Activated by Membrane-Type Matrix Metalloproteinases for Combined Cancer Magnetic Resonance Imaging and Therapy
  33. Comparison of latino and non-Latino patients with Ewing sarcoma
  34. Enhancing In Vivo Survival of Adipose-Derived Stromal Cells Through Bcl-2 Overexpression Using a Minicircle Vector
  35. Role of diffusion-weighted imaging in differentiating benign and malignant pediatric abdominal tumors
  36. Evaluation of the novel USPIO GEH121333 for MR imaging of cancer immune responses
  37. MR Imaging Features of Gadofluorine-Labeled Matrix-Associated Stem Cell Implants in Cartilage Defects
  38. Somatic Differentiation and MR Imaging of Magnetically Labeled Human Embryonic Stem Cells
  39. Comparison of the diagnostic value of MR imaging and ophthalmoscopy for the staging of retinoblastoma
  40. High-Resolution MR Imaging of the Orbit in Patients with Retinoblastoma
  41. Intravenous Ferumoxytol Allows Noninvasive MR Imaging Monitoring of Macrophage Migration into Stem Cell Transplants
  42. FDG PET/CT for the Evaluation of Normal Thymus, Lymphoma Recurrence, and Mediastinal Lymphoma in Pediatric Patients
  43. MR imaging of tumor-associated macrophages
  44. Dose Escalation Study of No-Carrier-Added 131I-Metaiodobenzylguanidine for Relapsed or Refractory Neuroblastoma: New Approaches to Neuroblastoma Therapy Consortium Trial
  45. A photonic crystal cavity-optical fiber tip nanoparticle sensor for biomedical applications
  46. Magnetic Resonance Imaging of Ferumoxide-Labeled Mesenchymal Stem Cells in Cartilage Defects: In Vitro and in Vivo Investigations
  47. Differentiation of Normal Thymus from Anterior Mediastinal Lymphoma and Lymphoma Recurrence at Pediatric PET/CT
  48. Engineering stem cells for treatment of osteochondral defects
  49. Labeling Stem Cells with Ferumoxytol, an FDA-Approved Iron Oxide Nanoparticle
  50. MRI of Tumor-Associated Macrophages with Clinically Applicable Iron Oxide Nanoparticles
  51. Labeling human embryonic stem-cell-derived cardiomyocytes for tracking with MR imaging
  52. Corrigendum
  53. Optical imaging of rheumatoid arthritis
  54. A phase I study of zoledronic acid and low-dose cyclophosphamide in recurrent/refractory neuroblastoma: A new approaches to neuroblastoma therapy (NANT) study
  55. Depicting adoptive immunotherapy for prostate cancer in an animal model with magnetic resonance imaging
  56. MR Signal Characteristics of Viable and Apoptotic Human Mesenchymal Stem Cells in Matrix-Associated Stem Cell Implants for Treatment of Osteoarthritis
  57. Radiological-pathological correlation of pleomorphic liposarcoma of the anterior mediastinum in a 17-year-old girl
  58. In Vivo Magnetic Resonance Imaging and Optical Imaging Comparison of Viable and Nonviable Mesenchymal Stem Cells with a Bifunctional Label
  59. Monitoring of Natural Killer Cell Immunotherapy Using Noninvasive Imaging Modalities
  60. Indocyanine green-enhanced imaging of antigen-induced arthritis with an integrated optical imaging/radiography system
  61. Breast Cancers: MR Imaging of Folate-Receptor Expression with the Folate-Specific Nanoparticle P1133
  62. Labeling Human Mesenchymal Stem Cells with Fluorescent Contrast Agents: the Biological Impact
  63. Implantation of Ferumoxides Labeled Human Mesenchymal Stem Cells in Cartilage Defects
  64. Unusual association of alveolar rhabdomyosarcoma with pancreatic metastasis: emerging role of PET-CT in tumor staging
  65. Labeling Human Embryonic Stem Cell-Derived Cardiomyocytes with Indocyanine Green for Noninvasive Tracking with Optical Imaging: An FDA-Compatible Alternative to Firefly Luciferase
  66. NK-cell tracking using non-invasive imaging modalities
  67. An optical imaging method to monitor stem cell migration in a model of immune-mediated arthritis
  68. Ectopic ureter associated with uterine didelphys and obstructed hemivagina: preoperative diagnosis by MRI
  69. Optical imaging of the peri-tumoral inflammatory response in breast cancer
  70. MR Imaging of Pediatric Arthritis
  71. Decreased aortic growth and middle aortic syndrome in patients with neuroblastoma after radiation therapy
  72. Accelerated stem cell labeling with ferucarbotran and protamine
  73. MR Imaging of Pediatric Arthritis
  74. Relaxation effects of ferucarbotran-labeled mesenchymal stem cells at 1.5T and 3T: Discrimination of viable from lysed cells
  75. The influence of ferucarbotran on the chondrogenesis of human mesenchymal stem cells
  76. New Perspectives on Bone Marrow Contrast Agents and Molecular Imaging
  77. Zelluläre Magnetresonanztomographie bei Arthritis
  78. Phase I Trial of Oral Irinotecan and Temozolomide for Children With Relapsed High-Risk Neuroblastoma: A New Approach to Neuroblastoma Therapy Consortium Study
  79. Essentials of Pediatric Radiology
  80. Optical Imaging of Cellular Immunotherapy against Prostate Cancer
  81. Improved fluorescence of indocyanine greenin vitroandin vivoafter simple cooling procedures
  82. Diagnostic value of PET/CT for the staging and restaging of pediatric tumors
  83. Pediatric liver tumors – a pictorial review
  84. Tracking of [18F]FDG-labeled natural killer cells to HER2/neu-positive tumors
  85. Cell tracking with optical imaging
  86. Receptor imaging of pediatric tumors: clinical practice and new developments
  87. Labeling Stem Cells with Fluorescent Dyes for non-invasive Detection with Optical Imaging
  88. Labeling hESCs and hMSCs with Iron Oxide Nanoparticles for Non-Invasive in vivo Tracking with MR Imaging
  89. MR imaging of ovarian tumors using folate-receptor-targeted contrast agents
  90. Imaging Characteristics of DHOG, a Hepatobiliary Contrast Agent for Preclinical MicroCT in Mice
  91. Detection of postoperative granulation tissue with an ICG-enhanced integrated OI-/X-ray System
  92. Monitoring neuer Immuntherapien für Prostatakarzinome mittels Magnetresonanztomographie
  93. Long-Term Outcome and Toxicities of Intraoperative Radiotherapy for High-Risk Neuroblastoma
  94. Cell labeling with the positive MR contrast agent Gadofluorine M
  95. MR imaging of antigen-induced arthritis with a new, folate receptor-targeted contrast agent
  96. Makrophagenspezifische MRT-Bildgebung bei antigeninduzierten Arthritiden
  97. 203
  98. MR imaging of therapy-induced changes of bone marrow
  99. Imaging of Tumor Angiogenesis: Current Approaches and Future Prospects
  100. Optical imaging of experimental arthritis using allogeneic leukocytes labeled with a near-infrared fluorescent probe
  101. MR-Diagnostik von Knochenmarkerkrankungen
  102. MRI of arthritis: Comparison of ultrasmall superparamagnetic iron oxide vs. Gd-DTPA
  103. MRT der Arthritis mit dem USPIO SH U 555 C: Optimierung des T1-Enhancements
  104. Ultrasmall Supraparamagnetic Iron Oxide-Enhanced Magnetic Resonance Imaging of Antigen-Induced Arthritis
  105. T1 and T2 relaxivity of intracellular and extracellular USPIO at 1.5T and 3T clinical MR scanning
  106. Ferumoxtran-10-enhanced MR imaging of the bone marrow before and after conditioning therapy in patients with non-Hodgkin lymphomas
  107. Mixture model approach to tumor classification based on pharmacokinetic measures of tumor permeability
  108. Ultrasmall Superparamagnetic Iron-Oxide–enhanced MR Imaging of Normal Bone Marrow in Rodents: Original Research
  109. Optimization of Gadodiamide Concentration for MR Arthrography at 3 T
  110. The Choice of Region of Interest Measures in Contrast-Enhanced Magnetic Resonance Image Characterization of Experimental Breast Tumors
  111. Comparison of iron oxide labeling properties of hematopoietic progenitor cells from umbilical cord blood and from peripheral blood for subsequent in vivo tracking in a xenotransplant mouse model XXX1
  112. Detection of hepatocellular carcinoma: comparison of Gd-DTPA- and ferumoxides-enhanced MR imaging
  113. Migration of Iron Oxide–labeled Human Hematopoietic Progenitor Cells in a Mouse Model: In Vivo Monitoring with 1.5-T MR Imaging Equipment
  114. In vivo tracking of genetically engineered, anti-HER2/neu directed natural killer cells to HER2/neu positive mammary tumors with magnetic resonance imaging
  115. Capacity of human monocytes to phagocytose approved iron oxide MR contrast agents in vitro
  116. Cell tracking with gadophrin-2: a bifunctional contrast agent for MR imaging, optical imaging, and fluorescence microscopy
  117. Decrease in Tumor Apparent Permeability-Surface Area Product to a MRI Macromolecular Contrast Medium Following Angiogenesis Inhibition with Correlations to Cytotoxic Drug Accumulation
  118. Phagozytose von verschiedenen, klinisch einsetzbaren superparamagnetischen MR-Kontrastmitteln durch humane Monozyten nach simpler in-vitro-Inkubation
  119. Quantification of Breast Tumor Microvascular Permeability with Feruglose-enhanced MR Imaging: Initial Phase II Multicenter Trial
  120. Macromolecular contrast medium (feruglose) versus small molecular contrast medium (gadopentetate) enhanced magnetic resonance imaging
  121. Targeting of Hematopoietic Progenitor Cells with MR Contrast Agents
  122. Highly efficient paramagnetic labelling of embryonic and neuronal stem cells
  123. Detection and Quantification of Breast Tumor Necrosis with MR Imaging
  124. MR Imaging of Hepatic Metastases
  125. Macromolecular contrast agents for MR mammography: current status
  126. Atypische Mykobakteriose der Mamma: MR-Diagnostik
  127. Iron-oxide-enhanced MR imaging of bone marrow in patients with non-Hodgkin's lymphoma: differentiation between tumor infiltration and hypercellular bone marrow
  128. Comparison between Gadopentetate and Feruglose (Clariscan™)-Enhanced MR-Mammography
  129. FDG–PET for detection of recurrences from malignant primary bone tumors: comparison with conventional imaging
  130. Whole-Body MR Imaging for Detection of Bone Metastases in Children and Young Adults
  131. Experimentelle Untersuchungen zur Wertigkeit von SPIO für die MRT des Knochenmarkes vor und nach Ganzkörperbestrahlung
  132. FDG-PET for detection of pulmonary metastases from malignant primary bone tumors: Comparison with spiral CT
  133. Carboxymethyldextran-A2-Gd-DOTA enhancement patterns in the abdomen and pelvis in an animal model
  134. Comparison of gadomer-17 and gadopentetate dimeglumine for differentiation of benign from malignant breast tumors with MR imaging
  135. Evaluation of the Accuracy of Gadobenate Dimeglumine-Enhanced MR Imaging in the Detection and Characterization of Focal Liver Lesions
  136. FDG-PET for detection of osseous metastases from malignant primary bone tumours: comparison with bone scintigraphy
  137. Assessing permeability alterations of the blood–bone marrow barrier due to total body irradiation: in vivo quantification with contrast enhanced magnetic resonance imaging
  138. CT of Metal Implants: Reduction of Artifacts Using an Extended CT Scale Technique
  139. Quantitative gadopentetate-enhanced MRI of breast tumors: Testing of different analytic methods
  140. Monitoring radiation-induced changes in bone marrow histopathology with ultra-small superparamagnetic iron oxide (USPIO)-enhanced MRI
  141. Tumor blood volume assays using contrast-enhanced magnetic resonance imaging: Regional heterogeneity and postmortem artifacts
  142. Correlation of dynamic contrast-enhanced MR imaging with histologic tumor grade: comparison of macromolecular and small-molecular contrast media.
  143. Quantification of the extraction fraction for gadopentetate across breast cancer capillaries
  144. MR imaging of thoracic tumors in pediatric patients.
  145. Macromolecular contrast media—enhanced MRI estimates of microvascular permeability correlate with histopathologic tumor grade
  146. Correlation of dynamic contrast-enhanced magnetic resonance imaging with histologic tumor grade: comparison of macromolecular and small-molecular contrast media
  147. High Resolution MRI of Small Joints: Impact of Spatial Resolution on Diagnostic Performance and SNR
  148. Evaluation of myelination and myelination disorders with turbo inversion recovery magnetic resonance imaging
  149. Macromolecular contrast media. A new approach for characterising breast tumors with MR-mammography
  150. Enhancement characteristics of liver metastases, hepatocellular carcinomas, and hemangiomas with Gd-EOB-DTPA: preliminary results with dynamic MR imaging
  151. Primäres Non-Hodgkin-Lymphom der Schädelkalotte bei einem 11jährigen Mädchen Krankheitsverlauf und Literaturübersicht
  152. Die Wertigkeit der 3-Phasen-Spiral-CT und der Magnetresonanztomographie in der präoperativen Diagnostik des Pankreaskarzinoms
  153. Hochdosierte Anwendung von Gd-DTPA-BMA (Gadodiamid) in der Diagnostik und Therapiebeurteilung maligner Knochentumoren
  154. Neue MR-Kontrastmittel in der Leberdiagnostik Erste klinische Ergebnisse mit hepatobiliärem Eovist® (Gadolinium-EOB-DTPA) und RES-spezifischem Resovist® (SH U 555 A)
  155. Einsatz von Gadoteridol in der MR-Diagnostik rheumatoider Gelenkveränderungen
  156. Regression eines hepatozellulären Adenoms nach Absetzen hormonaler Kontrazeption
  157. Acute bacterial pyelonephritis
  158. Adrenal hemorrhage
  159. Biliary atresia
  160. Choledochal cyst
  161. Desmoplastic small round cell tumor
  162. Ectopic ureterocele
  163. Foveolar hyperplasia: post prostaglandin therapy
  164. Henoch–Schönlein purpura
  165. Hydrops fetalis
  166. Infantile myofibromatosis
  167. Lymphoid follicular hyperplasia
  168. Mesenchymal hamartoma of the liver
  169. Middle aortic syndrome
  170. Midgut volvulus
  171. Nephroblastomatosis
  172. Oxalosis in an 11-year-old boy
  173. Pneumatosis cystoides intestinalis
  174. Preface
  175. Prune belly syndrome
  176. Renal cysts in tuberous sclerosis
  177. Renal vein thrombosis
  178. Torsion of the appendix testis
  179. Trilateral retinoblastoma
  180. Ureteropelvic junction obstruction
  181. Wilms’ tumor
  182. Pediatric tumors
  183. Congenital Malformations, Musculoskeletal System
  184. Stem Cell Tracking